SecBot SecBot
SECBOTREPLAY Home › Report › PMVP

PMVP · Tang Capital 9.99% stake

PMV Pharmaceuticals, Inc. · SC 13G/A filed Nov 16, 2026 at 16:15 ET

At the news

NEUTRALIMPACT 3/10

SC 13G/A filed Nov 16, 2026 at 16:15 ET

Tang Capital Management and related entities filed an amended Schedule 13G disclosing a 9.99% beneficial ownership stake in PMV Pharmaceuticals as of September 30, 2026, consisting of 7,572,727 shares of common stock (including 287,642 shares issuable upon warrant exercise) plus pre-funded warrants and additional warrants. The filing updates a prior 13G and reflects the group's passive investment status following the company's August 2026 public offering.

  • Tang Capital Management and Kevin Tang beneficially own 7,572,727 shares of PMVP common stock (9.99% of outstanding).
  • Stake includes 7,285,085 common shares and 287,642 shares issuable upon exercise of warrants.
  • Group also holds 11,000,000 pre-funded warrants and 14,040,000 warrants to purchase common stock.
  • Filing is an amendment to a prior Schedule 13G, maintaining passive investor status.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access